(0.13%) 5 161.25 points
(0.10%) 38 871 points
(0.12%) 18 023 points
(0.96%) $78.86
(0.47%) $2.15
(1.00%) $2 331.60
(2.63%) $27.39
(0.50%) $970.10
(0.03%) $0.929
(-0.28%) $10.84
(-0.20%) $0.795
(0.17%) $91.61
Live Chart Being Loaded With Signals
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19...
Stats | |
---|---|
今日成交量 | 73 397.00 |
平均成交量 | 460 746 |
市值 | 5.92M |
EPS | $0 ( 2024-03-29 ) |
下一个收益日期 | ( $-0.540 ) 2024-05-15 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.530 |
ATR14 | $0.00600 (0.50%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-01-05 | Springer Graig | Buy | 100 000 | Options |
2024-01-05 | Springer Graig | Buy | 25 000 | Options |
2024-01-05 | Sarnoff David | Buy | 25 000 | Options |
2024-01-05 | Pavell Jeff | Buy | 25 000 | Options |
2024-01-05 | Linsley Wayne | Buy | 25 000 | Options |
INSIDER POWER |
---|
100.00 |
Last 63 transactions |
Buy: 4 493 741 | Sell: 2 121 250 |
音量 相关性
Hoth Therapeutics Inc 相关性
你知道吗?
相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1,其中-1表示完全负相关(一个变量增加,另一个变量减少),1表示完全正相关(一个变量增加,另一个变量也增加),0表示没有相关性(变量之间没有关系)。
相关性可用于分析任何两个变量之间的关系,而不仅仅是股票。它通常用于金融、经济学、心理学等领域。
Hoth Therapeutics Inc 相关性 - 货币/商品
Hoth Therapeutics Inc 财务报表
Annual | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-2.30 |
FY | 2023 |
营收: | $0 |
毛利润: | $0 (0.00 %) |
EPS: | $-2.30 |
FY | 2022 |
营收: | $0 |
毛利润: | $-66 834.00 (0.00 %) |
EPS: | $-9.75 |
FY | 2021 |
营收: | $0.00 |
毛利润: | $0.00 (0.00 %) |
EPS: | $-28.95 |
Financial Reports:
No articles found.
Hoth Therapeutics Inc
Hoth Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-003 to treat inflammatory bowel diseases, as well as acne and psoriasis; HT-004 for treatment of asthma and allergies using inhalational administration; HT-006 to treat lung diseases resulting from bacterial infections; and HT-002, a novel peptide for treating COVID-19. The company is also developing BioLexa Platform, a proprietary, patented, drug compound platform which is in phase I clinical trial for the treatment of eczema; and HT-005 for treating patients with lupus. The company has license agreements with the George Washington University; the University of Maryland; Isoprene Pharmaceuticals, Inc.; the North Carolina State University; Chelexa BioSciences, Inc.; Zylö Therapeutics, Inc., and the University of Cincinnati. It also has a research collaboration agreement with Weill Cornell Medicine to develop HT-003. Hoth Therapeutics, Inc. was incorporated in 2017 and is headquartered in New York, New York.
关于 实时信号
此页面上呈现的实时信号有助于确定何时购买或出售NA. 信号具有高达1分钟的延迟;与所有市场信号一样,存在误差或错误的可能性。
实时交易信号不是绝对的,getagraph.com 对基于这些信号采取的任何行动概不负责,如《使用条款》中所述。这些信号是基于广泛的技术分析指标。